# OnCo record 3d-medicines (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/3d-medicines/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "3d-medicines" ;
  schema:name "3D Medicines"@en ;
  schema:alternateName "3D Medicines (Sichuan) Co., Ltd."@en, "3D Medicines Inc."@en, "思路迪"@en ;
  schema:description "3D Medicines is a Chinese biotechnology company that co-developed envafolimab, the first subcutaneous PD-L1 antibody, approved in China in 2021 for microsatellite instability-high solid tumours."@en ;
  schema:url <https://onco.cc/companies/3d-medicines/>, <https://www.3d-medicines.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?lead=3D%20Medicines> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/envafolimab/> ;
  onco:companies <https://onco.cc/companies/alphamab/> ;
  onco:trials <https://onco.cc/trials/nct06123754/>, <https://onco.cc/trials/nct04891198/>, <https://onco.cc/trials/nct03667170/>, <https://onco.cc/trials/nct05024214/>, <https://onco.cc/trials/nct03478488/>, <https://onco.cc/trials/nct05112991/> .